強直脊椎炎でFilgotinibは 椎体および後側方の炎症を 減少する: TORTUGA試験結果
Rheumatology 2022;61:2388–2397. doi: 10.1093/rheumatology/keab758
Maksymowych et al., assessed the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active ankylosing spondylitis in the TORTUGA trial. Correlations between changes in the inflammation score and clinical outcomes were also evaluated.